Dec 22 (Reuters) - AlloVir said on Friday it will discontinue three late-stage studies testing its experimental antiviral cell therapy after an independent safety board said the studies were unlikely to meet their main goals. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The $50 million purchase could turn into Nvidia's biggest investment.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
“When she died, we were told by her attorney that we were responsible for the taxes and property insurance during the time when the life tennant lives in the home.”
The tobacco giant will soon be allowed to sell a proven product in a proven market.
The recent pullback in price is a rare opportunity for investors to add to this high-flying stock.